CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Beijing Science Sun Pharmaceutical CoLtd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Beijing Science Sun Pharmaceutical CoLtd
No. 8,
Xingsheng Street, Beijing Economic Techn
Phone: +86 1067862500p:+86 1067862500 BEIJING, BEJ  100176  China Ticker: 300485300485
Business Summary
Beijing Science Sun Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of injectables. The Company's products are biological and biochemical drugs, covering three major drug use areas: cardiovascular and cerebrovascular diseases, immune diseases (anti-tumor) and nervous system diseases. The main products of immunomodulatory drugs are Saisheng Bozhi glycopeptide injection and Saisheng deoxyribonucleotide sodium injection. The main products of cardiovascular and cerebrovascular drugs are Saibai fibrinolytic enzyme injection, myo-aminopeptide injection and myo-aminopeptide injection. The main product of nervous system drugs is Saidian monosialotetrahexosylganglioside sodium injection (GM-1). The Company mainly conducts its businesses in the domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager BiaoMa 59 7/1/2001
Chief Financial Officer DongnaLiang 42 1/26/2024 1/26/2024
Chief Marketing Officer YinfuShen 58
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 532 (As of 12/31/2023)
Outstanding Shares: 481,666,400 (As of 9/30/2024)
Shareholders: 32,242
Stock Exchange: SHE
Fax Number: +86 1067862501


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, June 13, 2025